What is Stemgent?
Stemgent operates at the intersection of stem cell research and commercial reagent production, providing essential tools for cellular reprogramming. By collaborating with world-renowned scientists, the company develops innovative application solutions that simplify complex laboratory workflows. Its market position is defined by a commitment to high-quality, researcher-designed products that facilitate breakthroughs in regenerative medicine and developmental biology. As a critical supplier to the global scientific community, Stemgent bridges the gap between academic discovery and scalable laboratory utility, ensuring that researchers have access to the reagents necessary for high-fidelity cellular analysis.
How much funding has Stemgent raised?
Stemgent has raised a total of $40.8M across 5 funding rounds:
Series A
$6.5M
Series B
$14M
Other Financing Round
$2.7M
Private Equity
$6.3M
Private Equity
$11.3M
Series A (2008): $6.5M with participation from Morgenthaler Private Equity and HealthCare Ventures
Series B (2009): $14M led by Morgenthaler Private Equity and Frazier Healthcare Partners
Other Financing Round (2009): $2.7M supported by Morgenthaler Private Equity and HealthCare Ventures
Private Equity (2012): $6.3M featuring HealthCare Ventures LLC
Private Equity (2012): $11.3M backed by HealthCare Ventures LLC
Key Investors in Stemgent
Morgenthaler Private Equity
Morgenthaler is a premier venture capital and private equity firm with over 40 years of experience in creating valuable companies, specializing in investments within the Information Technology and Life Sciences sectors.
HealthCare Ventures LLC
HealthCare Ventures is a leading life science venture capital firm investing in pre-clinical or early clinical stage, focused companies with potential to transform patient care.
Frazier Healthcare Partners
Frazier Healthcare Partners is a prominent investment firm focused on the biopharmaceutical and healthcare services sectors, supporting companies that develop innovative treatments for complex medical conditions.
What's next for Stemgent?
With a history of sustained financial support, Stemgent is well-positioned to leverage its recent capital injection to expand its product portfolio and deepen its market penetration. The company's strategic roadmap likely involves accelerating the development of next-generation reprogramming reagents and enhancing its global distribution infrastructure. By maintaining strong relationships with its core venture partners, Stemgent is poised to capitalize on the increasing demand for standardized stem cell research tools, potentially exploring new therapeutic applications or strategic partnerships that align with its mission to advance cellular science on a global scale.
See full Stemgent company page
